Replicate Bioscience Reports Results from the P-I Study of RBI-4000 for Rabies
Shots:
- Replicate Bioscience highlighted preliminary data from the P-I study assessing RBI-4000’s (0.1mcg, 1mcg or 10mcg) safety, tolerability, and immunogenicity in patients (n=84) across the US, the preclinical study of which showed protection against rabies by generating antibodies & virus-specific T-cells
- In the study, RBI-4000 (0.1mcg) resulted in the surrogate metric of protection (RVNA≥0.5) in the majority of patients, a superior therapeutic index with favorable tolerability at all dose levels without SAEs
- RBI-4000 is an srRNA vaccine aimed at producing immune responses against the rabies virus for its prevention
Ref: Replicate Bioscience | Image: Replicate Bioscience
Related News:- Vividion Therapeutics Commences P-I Study of VVD-130850 for Advanced Solid and Hematologic Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
